ORTHO EVRA® and venous thromboembolism: an update

Contraception

Volumn 81, Issue 5, 2010, Pages 452-453

  Jick, Susan S ^a   Hagberg, Katrina W ^a   Kaye, James A ^b  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORGESTIMATE; CONTRACEPTIVE AGENT; DRUG DERIVATIVE; ETHINYLESTRADIOL; NORGESTREL;

ANTICOAGULATION; CONTROLLED STUDY; DRUG USE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LETTER; LUNG EMBOLISM; ORAL CONTRACEPTION; OUTCOME ASSESSMENT; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; FEMALE; NOTE;

CONTRACEPTIVE AGENTS, FEMALE; ETHINYL ESTRADIOL; FEMALE; HUMANS; NORGESTREL; VENOUS THROMBOEMBOLISM;

EID: 77950916344     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.12.016     Document Type: Letter

References (2)

1. Jick S.S., Kaye J.A., Russmann S., and Jick H. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 73 (2006) 223-228
2. Jick S.S., Kaye J.A., Li L., and Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 μg of ethinyl estradiol. Contraception 76 (2007) 4-7